Actinium shares jump 13.13% premarket as focus turns to advancing radiopharmaceutical pipeline and manufacturing progress.

Actinium Pharmaceuticals surged 13.13% in premarket trading following news of advancements in its radiopharmaceutical pipeline, including late-stage candidates Actimab-A and Iomab-B, and plans for a new cGMP manufacturing facility. The company’s focus on novel targeted radiotherapies, coupled with its proprietary Ac-225 production technology, has drawn investor attention despite ongoing financial challenges. The premarket rise suggests optimism around the firm’s long-term clinical and regulatory milestones, even as historical losses and cash burn remain key concerns.